Biocytogen (HKEX: 02315) will attend the upcoming 41st J.P. Morgan (JPM) Healthcare Conference week, and participate in several satellite conferences, including the Biotech Showcase and BIO Partnering at JPM, which are all to be held in San Francisco from January 9-12, 2023. The team will also present in the BFC conference and ACCESS CHINA before and after JPM week. Dr. Chaoshe Guo, VP of Biocytogen, and the antibody drug Business Development & Licensing (BDL) team will be in attendance to discuss Biocytogen’s innovative antibody technology platforms and antibody drug assets to explore partnerships with other pharmaceutical and biotech companies in attendance. The team’s full itinerary during JPM week is as follows:
Dr. Vivian Tian, Senior Director of the BDL team, will give a presentation at the Biotech Showcase, where she will introduce Biocytogen’s 6 therapeutic antibody discovery platforms for various targets and modalities, the company’s large-scale in vivo evidence-based drug efficacy screening platform, and the antibody-based drug assets generated by these platforms, including preclinical mAb/BsAb/BsADC assets and clinical assets. Details are summarized as follows:
1) 6 innovative fully human antibody discovery platforms for various targets and modalities:
2) Preclinical mAb/BsAb/BsADC assets:
In the past two years, Biocytogen has been continuously generating competitive antibody candidates or hits through Project Integrum, which can be further developed into various drug modalities, including mAb, BsAb, BsADC, TCR-mimic antibody and nanobody drugs. Our leading candidates to be discussed are as follows:
3) Clinical-stage assets
Five assets from Biocytogen’s pipeline have entered clinical trials. All of them were obtained from our high-throughput in vivo efficacy-based screening platform and demonstrated good efficacy and safety.
With our innovative antibody technology platforms and drug assets developed by these unique platforms, Biocytogen has established collaborations with many biopharmaceutical and biotech companies, including Merck KGaA, ADC therapeutics, Xencor, Tracon, BeiGene, Remegen, etc. We are excited to continue expanding our global partnerships to accelerate new drug development.
Contact us at BD-Licensing@biocytogen.com to set up a meeting. We look forward to discussing licensing and co-development opportunities with you!